195 related articles for article (PubMed ID: 24496317)
21. Interaction between herpesvirus entry mediator and HSV-2 glycoproteins mediates HIV-1 entry of HSV-2-infected epithelial cells.
Hu K; He S; Xiao J; Li M; Luo S; Zhang M; Hu Q
J Gen Virol; 2017 Sep; 98(9):2351-2361. PubMed ID: 28809154
[TBL] [Abstract][Full Text] [Related]
22. Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding.
McNicholl JM; Leelawiwat W; Whitehead S; Hanson DL; Evans-Strickfaden T; Cheng CY; Chonwattana W; Mueanpai F; Kittinunvorakoon C; Markowitz L; Dunne EF
Int J STD AIDS; 2017 Mar; 28(4):372-379. PubMed ID: 27179350
[TBL] [Abstract][Full Text] [Related]
23. Mechanistic Studies of Viral Entry: An Overview of Dendrimer-Based Microbicides As Entry Inhibitors Against Both HIV and HSV-2 Overlapped Infections.
Sepúlveda-Crespo D; Ceña-Díez R; Jiménez JL; Ángeles Muñoz-Fernández M
Med Res Rev; 2017 Jan; 37(1):149-179. PubMed ID: 27518199
[TBL] [Abstract][Full Text] [Related]
24. Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial.
Bender Ignacio RA; Perti T; Magaret AS; Rajagopal S; Stevens CE; Huang ML; Selke S; Johnston C; Marrazzo J; Wald A
J Infect Dis; 2015 Dec; 212(12):1949-56. PubMed ID: 26044291
[TBL] [Abstract][Full Text] [Related]
25. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
Keller MJ; Zerhouni-Layachi B; Cheshenko N; John M; Hogarty K; Kasowitz A; Goldberg CL; Wallenstein S; Profy AT; Klotman ME; Herold BC
J Infect Dis; 2006 Jan; 193(1):27-35. PubMed ID: 16323128
[TBL] [Abstract][Full Text] [Related]
26. No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults.
Tan DH; Kaul R; Raboud JM; Walmsley SL
AIDS; 2011 Jan; 25(2):207-10. PubMed ID: 21150556
[TBL] [Abstract][Full Text] [Related]
27. A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy.
Crostarosa F; Aravantinou M; Akpogheneta OJ; Jasny E; Shaw A; Kenney J; Piatak M; Lifson JD; Teitelbaum A; Hu L; Chudolij A; Zydowsky TM; Blanchard J; Gettie A; Robbiani M
PLoS One; 2009 Nov; 4(11):e8060. PubMed ID: 20011586
[TBL] [Abstract][Full Text] [Related]
28. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
[TBL] [Abstract][Full Text] [Related]
29. In Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical Mucosa.
Villegas G; Calenda G; Zhang S; Mizenina O; Kleinbeck K; Cooney ML; Hoesley CJ; Creasy GW; Friedland B; Fernández-Romero JA; Zydowsky TM; Teleshova N
Antimicrob Agents Chemother; 2016 Sep; 60(9):5459-66. PubMed ID: 27381393
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses.
Piret J; Lamontagne J; Bestman-Smith J; Roy S; Gourde P; Désormeaux A; Omar RF; Juhász J; Bergeron MG
J Clin Microbiol; 2000 Jan; 38(1):110-9. PubMed ID: 10618073
[TBL] [Abstract][Full Text] [Related]
31. Herpes simplex virus type 2 (HSV-2) genital shedding in HSV-2-/HIV-1-co-infected women receiving effective combination antiretroviral therapy.
Péré H; Rascanu A; LeGoff J; Matta M; Bois F; Lortholary O; Leroy V; Launay O; Bélec L;
Int J STD AIDS; 2016 Mar; 27(3):178-85. PubMed ID: 25769886
[TBL] [Abstract][Full Text] [Related]
32. ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.
Olesen R; Swanson MD; Kovarova M; Nochi T; Chateau M; Honeycutt JB; Long JM; Denton PW; Hudgens MG; Richardson A; Tolstrup M; Østergaard L; Wahl A; Garcia JV
J Clin Invest; 2016 Mar; 126(3):892-904. PubMed ID: 26854925
[TBL] [Abstract][Full Text] [Related]
33. Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.
Vibholm L; Reinert LS; Søgaard OS; Paludan SR; Østergaard L; Tolstrup M; Melchjorsen J
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1404-11. PubMed ID: 22867119
[TBL] [Abstract][Full Text] [Related]
34. Variability of human immunodeficiency virus-1 in the female genital reservoir during genital reactivation of herpes simplex virus type 2.
LeGoff J; Roques P; Jenabian MA; Charpentier C; Brochier C; Bouhlal H; Gresenguet G; Frost E; Pepin J; Mayaud P; Belec L;
Clin Microbiol Infect; 2015 Sep; 21(9):873.e1-9. PubMed ID: 26003280
[TBL] [Abstract][Full Text] [Related]
35. Bowman‒Birk Inhibitor Suppresses Herpes Simplex Virus Type 2 Infection of Human Cervical Epithelial Cells.
Liu Y; Xu XQ; Zhang B; Gu J; Meng FZ; Liu H; Zhou L; Wang X; Hou W; Ho WZ
Viruses; 2018 Oct; 10(10):. PubMed ID: 30322047
[TBL] [Abstract][Full Text] [Related]
36. Impact of asymptomatic herpes simplex virus type 2 infection on mucosal homing and immune cell subsets in the blood and female genital tract.
Shannon B; Yi TJ; Thomas-Pavanel J; Chieza L; Janakiram P; Saunders M; Tharao W; Huibner S; Remis R; Rebbapragada A; Kaul R
J Immunol; 2014 Jun; 192(11):5074-82. PubMed ID: 24760150
[TBL] [Abstract][Full Text] [Related]
37. The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in-vitro.
Jennings R; Clegg A
J Antimicrob Chemother; 1993 Jul; 32(1):71-82. PubMed ID: 7693643
[TBL] [Abstract][Full Text] [Related]
38. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics.
Corey L; Wald A; Celum CL; Quinn TC
J Acquir Immune Defic Syndr; 2004 Apr; 35(5):435-45. PubMed ID: 15021308
[TBL] [Abstract][Full Text] [Related]
39. HSV-2 Cellular Programming Enables Productive HIV Infection in Dendritic Cells.
Crisci E; Svanberg C; Ellegård R; Khalid M; Hellblom J; Okuyama K; Bhattacharya P; Nyström S; Shankar EM; Eriksson K; Larsson M
Front Immunol; 2019; 10():2889. PubMed ID: 31867020
[TBL] [Abstract][Full Text] [Related]
40. Resveratrol suppresses nuclear factor-kappaB in herpes simplex virus infected cells.
Faith SA; Sweet TJ; Bailey E; Booth T; Docherty JJ
Antiviral Res; 2006 Dec; 72(3):242-51. PubMed ID: 16876885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
